Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05819983
Other study ID # DV202303.01
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 25, 2023
Est. completion date March 6, 2023

Study information

Verified date April 2023
Source Universitas Padjadjaran
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Scabies is a skin disease characterized by intense itching that worsens at night. It is very contagious, still has a high occurrence rate, and impacts patient quality of life. The use of scabicide followed by a clean and healthy lifestyle is the principle of scabies therapy. The primary treatment option for scabies is permethrin 5% cream. Ivermectin is an alternate treatment for scabies.


Description:

Permethrin acts by disrupting the sodium channel current, resulting in delayed repolarization, paralysis, and death of the parasite. Sodium channels are ubiquitous and therefore permethrin acts at all stages of the life cycle of the parasite. Permethrin 5% cream is applied overnight once a week for two weeks to the entire body. This drug has a number of negative side effects, such as being expensive, uncomfortable, less applicable, and in some cases resistant to permethrin. Ivermectin is an alternate treatment for scabies and should be administered twice, one week apart. Ivermectin acts by binding selectively and with high affinity to glutamate-gated chloride ion channels, which are present in invertebrate nerve and muscle cells, resulting in paralysis and death of the parasite. Two doses of ivermectin one week apart are recommended for scabies treatment. Due to its specific site of action, ivermectin may not be effective against the younger stages of the parasite inside the egg because the nervous system has not yet developed. This drug is safe, more affordable, more practical to use, and has minimal side effects. The disadvantage of ivermectin is it does not kill all the stages of S. scabiei, necessitating multiple doses. According to several earlier research, topical permethrin is just as effective as oral ivermectin at one or two doses. There hasn't been any research on how well three doses of oral ivermectin treat scabies. As a result of no data, our trial is looking forward to answering the comparison of the effectiveness between three dosages of oral ivermectin, two dosages of oral ivermectin, and two applications of topical permethrin in scabies patients.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date March 6, 2023
Est. primary completion date February 1, 2023
Accepts healthy volunteers No
Gender All
Age group 6 Years and older
Eligibility Inclusion Criteria: - Male or female - Age 6 years or above - Body weight 15kg or above - Clinical establishment of diagnosed scabies Exclusion Criteria: - Pregnant or breastfeeding woman - Scabies with secondary infection - Scabies with eczematization - History of receiving scabies treatment in the last four weeks - History of drug hypersensitivity

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ivermectin Tablets
Ivermectin 200µg/kg BW
Permethrin Cream
Permethrin cream 5%

Locations

Country Name City State
Indonesia Ciumbuleuit Public Health Centre Bandung West Java

Sponsors (1)

Lead Sponsor Collaborator
Universitas Padjadjaran

Country where clinical trial is conducted

Indonesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary The severity of scabetic lesions Determined by counting the number of lesions and graded as:
0 = Free of lesions (no scabies) 10 or fewer lesions = Mild 11-49 lesions= Moderate 50 or more lesions= Severe
5 weeks
Primary The severity of pruritus Evaluated by the patients graded on a scale 0-10 (using VAS score):
0= No pruritus 1-3= Mild 4-6= Moderate 7-10= Severe
5 weeks
Secondary Clinical improvement Defined as a reduction in both the number of lesions and symptoms and graded as:
Mild= Less than 50% reduction in the number of lesions and pruritus Moderate= More than or equal to 50% reduction in the number of lesions and pruritus Good= Complete clearance of the lesion and pruritus
4 weeks
Secondary Side effects Evaluated the side effects after using oral ivermectin or permethrin 5% cream. 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT02572986 - A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies Phase 3
Completed NCT00884728 - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory N/A
Completed NCT05025696 - Efficacy and Side Effects of Blacksoap® as Adjuvant Therapy of Scabies N/A
Completed NCT04205669 - Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon Phase 4
Completed NCT02254564 - PCR (Polymerase Chain Reaction) Assay for Diagnosis of Sarcoptes Scabiei
Not yet recruiting NCT06404333 - Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15) Phase 2
Completed NCT03676140 - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 3
Recruiting NCT05875441 - Efficacy and Safety Study of Moxidectin in Adults With Scabies Phase 2
Completed NCT02978508 - Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies. Phase 3
Recruiting NCT04332068 - Ivermectin Safety in Small Children Phase 2
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Not yet recruiting NCT06380452 - Therapy for Scabies With Two Differently Concentrated Permethrin Creams Phase 3
Completed NCT00604084 - Veron Scabies Education and Eradication Program N/A
Completed NCT02485717 - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies Phase 3
Completed NCT02485704 - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies Phase 3
Recruiting NCT05310734 - PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies Phase 4
Recruiting NCT04931680 - Risk Factors for Treatment Failure of Scabies in Autochthonous Populations of French Guiana (GUYAGALE)
Completed NCT06396507 - Sulfur vs. Different Regimes of Permethrin for Scabies Phase 3
Completed NCT05862701 - Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies Phase 1
Not yet recruiting NCT05500326 - Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study) Phase 2